Abstracts Archive - Page 154 of 2607 - ACR Meeting Abstracts

Abstract Number: 0731 • ACR Convergence 2025
The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Linda Zhu¹, Arielle Mendel², Carolyn Ross³ and Jean-Paul Makhzoum¹, ¹Universite de Montreal, Montreal, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³University of Montreal, Longueuil, Canada
Background/Purpose: The objective of this systematic review is to assess the effectiveness of leflunomide in the treatment of new-onset, refractory or relapsing giant cell arteritis…
Abstract Number: 2279 • ACR Convergence 2025
Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial
Koray Tascilar¹, Mikkel Ostergaard², Verena Schoenau³, Uta Kiltz⁴, Xenofon Baraliakos⁴, David Kofler⁵, Martin Feuchtenberger⁶, Ulrike Steffen⁷, Mario Zaiss⁸, Michael Zaenker⁹, Reinhard Voll¹⁰, Cornelia. Glaser¹¹, Holger Bang¹², Eugen feist¹³, Gerd Burmester¹⁴, Kirsten Karberg¹⁵, Joachim Strunk¹⁶, Juan Cañete¹⁷, Esperanza Naredo¹⁸, Mária Filková¹⁹, Ladislav Šenolt¹⁹, Georg Schett²⁰ and Juergen Rech⁷, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, ³- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵University of Cologne, Cologne, Germany, ⁶MED | BAYERN OST GmbH, Fachbereich Rheumatologie, Burghausen, Germany, Burghausen, Bayern, Germany, ⁷Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, Erlangen, Bayern, Germany, ⁸¹Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, Erlangen, Bayern, Germany, ⁹Immanuel Klinikum Bernau , Herzzentrum Brandenburg, Abteilung Innere Medizin, Bernau, Germany, Berlin, Germany, ¹⁰University Medical Center Freiburg, Freiburg, Germany, ¹¹Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, Freiburg, Baden-Wurttemberg, Germany, ¹²Orgentec, Mainz, Germany, ¹³Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ¹⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹⁵Praxis für Rheumatologie und Innere Medizin, Rheumatologie, Berlin, Germany, Berlin, Germany, ¹⁶Krankenhaus Porz am Rhein GmbH, Rheumaklinik, Köln (Porz), Germany, Köln-Porz, Germany, ¹⁷Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁸Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute FJD-UAM, Madrid, Spain, MADRID, Spain, ¹⁹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: A 6-month intervention with abatacept in the ARIAA trial (EUDRA-CT 2014–000555–93) significantly retarded the development of RA compared to placebo in ACPA-positive individuals with…
Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
Abstract Number: 0319 • ACR Convergence 2025
Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Danielle Madison¹, Adriana Morales Rivera², Dylon Collins², Isabel Lam², Daniel Khokhar², Garrett Snyder², Anthony Thompson², Mark Soliman², Daniela Carralero Somoza² and Michael Sabina², ¹Lakeland Regional Medical Center, Lakeland, FL, ²Lakeland Regional Medical Center, Lakeland
Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability and the most common rheumatological condition worldwide. Weight management has been recognized as a key…
Abstract Number: 0084 • ACR Convergence 2025
Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts
Keita Okamoto¹, Yasuto Araki², Yoshimi Aizaki², Hiroshi Kajiyama³, Kazuhiro Yokota², Yu Funakubo², Yuho Kadono⁴, Yuji Akiyama⁵ and Toshihide Mimura⁶, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-chou, Iruma-gun, Saitama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan, ⁴Department of Orthopaedic Surgery, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, ⁵Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-machi, Iruma-gun, Saitama, Japan, ⁶Saitama Seikeikai Hospital, Higashimatsuyama, Saitama, Japan
Background/Purpose: Rheumatoid arthritis synovial fibroblasts (RASFs) produce various matrix metalloproteinases (MMPs), cytokines, and chemokines. Histone lysine methylation has been shown to play an important role…
Abstract Number: 0733 • ACR Convergence 2025
Cerebrovascular Accidents in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study
Saman Tanveer¹, Pranathi Bandarupalli², Vineeth Potluri³, Fatima Tanveer⁴ and Abdullah Saeed⁵, ¹The University of Chicago, Chicago, IL, ²Mercy St Vincent Medical Center, Toledo, OH, ³Mercy Health St. Vincent Medical Center, Toledo, OH, ⁴CMH Lahore Medical College and Institute of Dentistry, Lahore, Punjab, Pakistan, ⁵John H. Stroger Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: To assess the characteristics, interventions, and outcomes of cerebrovascular accidents (CVAs) in people with giant cell arteritis (GCA). Strokes are uncommon in this population,…
Abstract Number: 0730 • ACR Convergence 2025
Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
Victor Pimentel-Quiroz¹, Alvaro Oyarce-Calderón², Allison Figueroa-Sánchez³, Leonor León-Yaurimucha³, Rocío Gamboa-Cárdenas⁴, Zoila Rodríguez-Bellido⁵, Risto Perich-Campos⁶, Graciela Alarcón⁷ and Manuel Ugarte-Gil⁸, ¹Universidad Científica del Sur, San Isidro, Peru, ²Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA, ⁸Universidad Cientifica del Sur, Lima, Peru
Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been…
Abstract Number: 0727 • ACR Convergence 2025
Higher rates of severe sensorineural hearing loss in granulomatosis with polyangiitis (GPA) compared to other antineutrophil cytoplasmic antibody (ANCA) associated vasculitis
Sehreen Mumtaz¹, Kindalem Fentie², Joseph Parker², Emily Craver¹, Vikas Majithia³ and Andy Abril⁴, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Mayo Clinic Hospital, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville
Background/Purpose: Hearing loss in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is one of the commonly reported manifestations of organ damage in AAV with predominantly…
Abstract Number: 0743 • ACR Convergence 2025
Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
David O'Dea¹, Guy Katz¹, Belen Arevalo Molina¹, Adam Jarvie², Mark Matza¹, Ana Fernandes¹, John Stone³ and Sebastian H Unizony⁴, ¹Massachusetts General Hospital, Boston, MA, ²Emory University School of Medicine, Atlanta, GA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The optimal duration of tocilizumab (TCZ) treatment for giant cell arteritis (GCA) is unclear. Observational studies have shown that 50-60% of patients relapse after…
Abstract Number: 0740 • ACR Convergence 2025
Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Carmen Secada-Gómez¹, Javier Loricera², Adrian Martin-Gutierrez³, Santos Castañeda⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Aortitis associated to Giant cell arteritis (GCA) (GCA-aortitis) is one of the most severe manifestation of GCA. Tocilizumab (TCZ) has demonstrated efficacy in large-vessel…
Abstract Number: 0763 • ACR Convergence 2025
Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience
wendy Perdomo, Sean Welch and Timothy Wilson, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is predominantly large vessel vasculitis that has a specific prediliction for vasculature of the head, eyes and jaw and if…
Abstract Number: 0765 • ACR Convergence 2025
Rural Access to Physical Therapy for Osteoarthritis Rehabilitation (RAPTOR): A Pilot Feasibility Study
Allyn Bove, Emma Zavacky, Hallie Zeleznik, Christopher Bise, Charity Patterson, Bambang Parmanto and G Kelley Fitzgerald, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Individuals who live in rural areas are more likely to experience knee osteoarthritis-related disability and less likely to be referred to physical therapy for…
Abstract Number: 0751 • ACR Convergence 2025
Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis
Lisa Christ¹, Shalina Taylor², Yilin Xu², Rhiya Sharma², Thierry Sornasse², Yingtao Bi², Heath Guay², Arathi Setty³, Ana Romero⁴, Peter Merkel⁵, Eugenio de Miguel⁶, Christian Dejaco⁷ and Cornelia Weyand⁸, ¹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ²AbbVie Inc, North Chicago, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie, Barcelona, Spain, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁸Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester
Background/Purpose: Interleukin-6 (IL-6) and interferon-gamma (IFNγ) have been identified as key drivers in the pathogenesis of giant cell arteritis (GCA), that promote disease progression. The…
Abstract Number: 0503 • ACR Convergence 2025
Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
Andrey E. Karateev¹, Sofia Kuzkina², Alina Egorova³ and Elena Y. Polishchuk¹, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²R-Pharm, Moscow, Russia, ³R-Pharm JSC, Moscow, Russia
Background/Purpose: Pain is one of the most debilitating symptoms of rheumatoid arthritis (RA) and a major contributor to reduced quality of life. Persistent joint pain…
Abstract Number: 0737 • ACR Convergence 2025
Effectiveness and Safety of Janus Kinase Inhibitors in Giant Cell Arteritis. Real-World Clinical Practice Study and Literature Review
Ana Serrano-Combarro¹, Fernando Lopez Gutierrez², Javier Loricera³, toluwalase Tofade⁴, Diana Prieto-Peña⁵, Susana Romero-Yuste⁶, Eugenio de Miguel⁷, Anne Riveros frutos⁸, DALIFER FREITES⁹, Ivan Ferraz Amaro¹⁰, Santos Castañeda¹¹, Eztizen Labrador-Sanchez¹², Olga Maiz¹³, Elena Becerra-Fernández¹⁴, Javier Narváez¹⁵, Eva Galíndez Agirregoikoa¹⁶, Ismael González¹⁷, Ana Urruticoechea-Arana¹⁸, Angel Ramos Calvo¹⁹, Patricia Moya Albarado²⁰, Sebastian H Unizony²¹ and Ricardo Blanco²², ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Massachussetts General Hospital, Boston, MA, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁶University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁷Hospital Universitario La Paz, Madrid, Spain, ⁸Hospital Germans Trias i Pujol, Barcelona, Spain, ⁹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ¹⁰Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹²Hospital Universitario San Pedro, Laguardia, Spain, ¹³Hospital Universitario de Donostia, San Sebastián, Pais Vasco, Spain, ¹⁴Hospital Universitario de Elda, Alicante, Comunidad Valenciana, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁷Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ¹⁸Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Castilla y Leon, Spain, ²⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Patients with giant cell arteritis (GCA) can relapse despite glucocorticoids, methotrexate and tocilizumab treatment. The JAK/STAT signalling pathway is involved in the pathogenesis of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].